The ascension of copyright’s drug initially ignited significant expansion in the medicinal sector, producing a image of easy profits. However, investing in companies solely reliant on top-selling drugs like Sildenafil presents considerable dangers. Intellectual property expiry has resulted in alternative rivalry, decreasing sales portion and pot… Read More

The recent surge in investments into specialized pharmaceutical companies, particularly those focusing on experimental therapies and complex drug development programs, has fueled what some are calling "High Investor Pharma." While the potential for revolutionary treatments and substantial returns is clear, the linked risks are also considerable.… Read More